Apalutamide yields deep PSA response, improved patient-related end points
February 18th 2022“Not only does a deep PSA response identify patients who will have improved survival and progression-free outcomes, but also it is also associated with maintenance of health-related quality of life, improved patient reported physical wellbeing, and a reduced risk of worsening pain and fatigue intensity,” said Eric Jay Small, MD.
PSMA-PET imaging may miss small pelvic nodal metastases in men with prostate cancer
October 19th 2021"Clinicians taking care of patients with high-risk prostate cancer being assessed for prostatectomy can use a positive [PSMA] PET scan as a true positive, whereas a negative scan cannot be used to exclude disease or inform nodal dissection," wrote Joseph Osborne, MD, PhD, and colleagues.
White paper addresses ethical considerations for older patients with incontinence
October 15th 2021"As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on," says Anne M. Suskind, MD, MS, FACS, FPMRS.
Dr. Suskind overviews new white paper focused on incontinence in older patients
October 11th 2021As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on,” says Anne M. Suskind, MD, MS, FACS, FPMRS.
Understanding patterns in prostate genomic testing using SEER and GPS assay
October 4th 2021In a recent study presented at the 2021 AUA Annual Meeting, Scarlett Gomez, MPH, PhD, and co-authors investigated the determinants of selecting active surveillance/watchful waiting as a treatment path for patients with localized, low-risk prostate cancer.
Study launched exploring novel BET inhibitor plus pembrolizumab and enzalutamide in mCRPC
March 17th 2021The study is evaluating the triplet in patients with metastatic castration-resistant prostate cancer who have become resistant to first-line treatment with an androgen receptor signaling inhibitor.